New drug duo shows promise in shrinking tough cancers

NCT ID NCT03468426

Completed Disease control Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a combination of two experimental drugs (BI 836880 and ezabenlimab) in 252 adults with advanced non-squamous lung cancer and other solid tumors. The first part found the safest dose; the second part checked if the combo could shrink tumors. Participants received infusions every 3 weeks as long as they benefited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEOPLASMS NON-SQUAMOUS NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Alfred Hospital

Melbourne, Victoria, 3004, Australia
Asan Medical Center

Seoul, 05505, South Korea
Beverly Hills Cancer Center

Beverly Hills, California, 90211, United States
CTR Eugène Marquis

Rennes, 35042, France
CTR Georges-François Leclerc

Dijon, 21079, France
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Dom Lekarski S.A.

Szczecin, 70-784, Poland
European Health Center Otwock

Otwock, 05-462, Poland
HOP Civil

Strasbourg, 67091, France
HOP Nord Laennec

Saint-Herblain, 44800, France
HOP Timone

Marseille, 13385, France
Hospital Clinico Universitario De Valencia

Valencia, 46010, Spain
Hospital Clínic de Barcelona

Barcelona, 08036, Spain
Hospital Universitari Vall D Hebron

Barcelona, 08035, Spain
Huntsman Cancer Institute

Salt Lake City, Utah, 84112, United States
INS Curie

Paris, 75005, France
JSC "Group of Companies "Medsi"

Moscow, 125284, Russia
Kyiv City Clinical Oncological Center

Kyiv, 3115, Ukraine
MED POLONIA SP Z O O, Clinical Trials Department,Poznan

Poznan, 60-693, Poland
Mandziuk Slawomir Specialist Medical Practice

Lublin, 20-093, Poland
Medical and Preventive Treatment Inst. Volyn Regional, Lutsk

Lutsk, 43018, Ukraine
Municipal Non-profit Enterprise "City Clinical Hospital #4" of Dnipro City Council

Dnipropetrovks, 49102, Ukraine
NCKUH

Tainan, 704, Taiwan
National Taiwan University Hospital

Taipei, 100, Taiwan
Peninsula & South Eastern Oncology Group

Frankston, Victoria, 3199, Australia
Queen Mary Hospital

Hong Kong, Hong Kong
Royal Free Hospital

London, NW3 2QG, United Kingdom
Royal North Shore Hospital-St Leonards-20807

St Leonards, New South Wales, 2065, Australia
SBHI "Saint-Petersburg Clinical Research Center of Specialized Types of Medical Care (Oncological)"

Saint Petersburg, 197758, Russia
Seoul National University Bundang Hospital

Seongnam, 13620, South Korea
Seoul National University Hospital

Seoul, 03080, South Korea
State Budget Healthcare Institution "Volgograd Regional Clinical Oncology Dispensary"

Volgograd, 400138, Russia
University Clinical Center, Gdansk

Gdansk, 80-952, Poland
University of Alabama at Birmingham

Birmingham, Alabama, 35249, United States
Universitätsklinikum Augsburg

Augsburg, 86156, Germany
Universitätsklinikum Carl Gustav Carus Dresden

Dresden, 01307, Germany
Universitätsklinikum Frankfurt

Frankfurt am Main, 60528, Germany
Universitätsklinikum Regensburg

Regensburg, 93053, Germany
Universitätsmedizin der Johannes Gutenberg-Universität Mainz

Mainz, 55131, Germany
Vinnytsia Regional Clinical Oncological Dispensary

Vinnytsia, 21029, Ukraine
Virginia Cancer Specialists, PC

Fairfax, Virginia, 22031, United States
Westmead Hospital

Westmead, New South Wales, 2145, Australia
Winship Cancer Institute

Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.